REFERENCES
2. Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880.
3. Caporali R, Kadakia A, Howell O, et al. A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies after switching from an initial tumor necrosis factor inhibitor. Adv Ther. 2024;41:3706-21.
4. Mohammadi P, Hesari M, Chalabi M, Salari F, Khademi F. An overview of immune checkpoint therapy in autoimmune diseases. Int Immunopharmacol. 2022;107:108647.
5. Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022;21:103056.
6. Scott IC, Rijsdijk F, Walker J, et al. Do genetic susceptibility variants associate with disease severity in early active rheumatoid arthritis? J Rheumatol. 2015;42:1131-40.
7. Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet. 2009;41:1313-8.
8. Barton A, Thomson W, Ke X, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet. 2008;17:2274-9.
9. Orozco G, Martín J. Identification of new susceptibility markers for rheumatoid arthritis and systemic lupus erythematosus in the STAT4 gene. Per Med. 2008;5:169-74.
10. Mohren L, Doege A, Miroschnikov N, Dräger O, Busch MA, Dünker N. Role of protein tyrosine phosphatase receptor type E (PTPRE) in chemoresistant retinoblastoma. Int J Mol Sci. 2024;25:4572.
11. Lippert AH, Paluch C, Gaglioni M, et al. Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases. Immunity. 2024;57:256-70.e10.
12. Bek S, Bojesen AB, Nielsen JV, et al. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J. 2017;17:403-11.
13. Prasad P, Kumar A, Gupta R, Juyal RC, Thelma BK. Caucasian and Asian specific rheumatoid arthritis risk loci reveal limited replication and apparent allelic heterogeneity in north Indians. PLoS One. 2012;7:e31584.
14. Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet. 2008;40:1216-23.
15. Ferreiro-Iglesias A, Montes A, Perez-Pampin E, et al. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J. 2016;16:137-40.
16. Plant D, Prajapati R, Hyrich KL, et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012;64:665-70.
17. Zervou MI, Myrthianou E, Flouri I, et al. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One. 2013;8:e74375.
18. Canhão H, Rodrigues AM, Santos MJ, et al. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. Biomed Res Int. 2015;2015:490295.
19. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010;62:1849-61.
20. Lee YH, Bae SC. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2016;36:837-44.
21. Sohani ZN, Anand S, Meyre D, et al. Q-Genie. 2015; pp. 1-4. Available from: http://fhs.mcmaster.ca/pgp/links.html [Last accessed on 29 Sep 2025].
22. Sohani ZN, Sarma S, Alyass A, et al. Empirical evaluation of the Q-Genie tool: a protocol for assessment of effectiveness. BMJ Open. 2016;6:e010403.
23. Sohani ZN, Meyre D, de Souza RJ, et al. Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet. 2015;16:50.
24. Schwarzer G, Carpenter JR, Rücker G. Meta-analysis with R. Cham: Springer International Publishing; 2015.
26. Vaz-Drago R, Custódio N, Carmo-Fonseca M. Deep intronic mutations and human disease. Hum Genet. 2017;136:1093-111.
27. Ingelman-Sundberg M, Nebert DW, Lauschke VM. Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling. Hum Genomics. 2023;17:105.
28. Whyte ML, Smith KA, Buchberger A, et al. The roseoloviruses downregulate the protein tyrosine phosphatase PTPRC (CD45). J Virol. 2021;95:e0162820.
29. Alborzian Deh Sheikh A, Akatsu C, Abdu-Allah HHM, et al. The protein tyrosine phosphatase SHP-1 (PTPN6) but not CD45 (PTPRC) is essential for the ligand-mediated regulation of CD22 in BCR-ligated B cells. J Immunol. 2021;206:2544-51.
30. Barashdi MA, Ali A, McMullin MF, Mills K. Protein tyrosine phosphatase receptor type C (PTPRC or CD45). J Clin Pathol. 2021;74:548-52.
31. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360-72.
32. Stepanov AA, Malsagova KA, Kopylov AT, et al. Determination of heterogeneous proteomic and metabolomic response in anti-TNF and anti-IL-6 treatment of patients with rheumatoid arthritis. Life. 2023;13:596.
33. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159-67.
34. Li YR, Keating BJ. Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations. Genome Med. 2014;6:91.
